Friday, December 5, 2008
Evening Symposia: 6:00 p.m. – 10:00 p.m.
- T-Cell and B-Cell Non-Hodgkin Lymphoma Revisited: Therapeutic Paradigms and Advances
- Critical Advances in the Management of Immune Thrombocytopenic Purpura
- Bone Marrow Failure Syndromes: Optimizing Outcomes Worldwide Through Disease Understanding
- Management of Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers, and Novel Treatment Strategies
- The Changing Face of Thrombocytopenia Management: A Focus on Improving Patient
Outcomes - Multiple Myeloma: Finding Your Way Through the Treatment Maze – Selecting the Best Treatment in the Era of Novel Agents
- Clinical Crossroads: Factors Critical to Successful Patient Management in Lymphoproliferative Disorders
- Debating the Key Clinical Questions for the Management of Patients With Multiple Myeloma
- Integrating New Developments in MDS Into Clinical Practice
- New Perspectives, New Strategies in Venous Thromboembolic Disease
T-Cell and B-Cell Non-Hodgkin Lymphoma Revisited: Therapeutic Paradigms and Advances
This program is sponsored by Physicians'Education Resource and supported by Allos Therapeutics, Inc.
| Location: | Hilton San Francisco – Continental Ballroom 5 |
|
| Speakers: | Eric Hsi, MD, Cleveland Clinic Foundation, Cleveland, OH
|
|
| Randy Gascoyne, MD, University of British Columbia, Vancouver, British Columbia, Canada
|
||
| David Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY |
Therapeutic options in non-Hodgkin lymphoma (NHL) are rapidly evolving, making therapy decisions more complicated. This symposium will address the latest developments in therapy for T-cell and B-cell non-Hodgkin lymphoma. In the T-cell section, after discussion of the pathophysiology of T-cell NHL, recent therapeutic advances in peripheral T-cell lymphoma will be assessed. Clinical scenarios will illustrate in a practical context the application of available clinical data to the treatment of cutaneous T-cell lymphoma. In the latter part of the program, recent advances in B-cell lymphomas, such as central-nervous-system lymphoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma will be discussed.
For more information, contact:
Dana Ritchie, Physicians' Education Resource
Phone: 214-367-3482
Fax: 214-367-3303
Critical Advances in the Management of Immune Thrombocytopenic Purpura
This program is sponsored by Physicians'Education Resource and supported by Amgen Oncology.
|
This symposium will address the significant new advances in ITP therapy, specifically the application of thrombopoietin receptor agonists. An overview of the pathophysiology of ITP will set the stage for case-based lectures. An initial case presentation will review current treatment standards for newly diagnosed patients with ITP. The subsequent case presentations will feature discussions on new therapeutic options in ITP and will address treatment recommendations for splenectomized, nonsplenectomized, and refractory patients. A debate will be held on two treatment opinions for a patient with refractory ITP following steroid therapy in order to contrast different options and the relative merits and drawbacks of each.
For more information, contact:
Dana Ritchie, Physicians' Education Resource
Phone: 214-367-3482
Fax: 214-367-3303
Bone Marrow Failure Syndromes: Optimizing Outcomes Worldwide Through Disease Understanding
This program is sponsored by the Cleveland Clinic Center for Continuing Education and supported by Celgene Corporation.
| Location: | Moscone Center West, Level 2, Room 2000/2002/2004 | |
| Speakers: | Mikkael Sekeres, MD, Taussig Cancer Center, Cleveland Clinic, Cleveland OH
|
|
| Jaroslaw P. Maciejewski, MD PhD, Taussig Cancer Center, Cleveland Clinic, Cleveland OH
| ||
| Aristoteles A.N. Giagoundis, MD, St. Johannes Hospital, Duisburg, Germany
|
||
| James G. Herman, MD, The Johns Hopkins University, Baltimore, MD
|
||
| Pierre Fenaux, MD, Avicenne Hospital, Bobigny, France
|
||
| Alice Houk, MS, Aplastic Anemia and Myelodysplastic Syndromes International Foundation, Inc., Churchton, MD
|
||
| Louis Degennaro, PhD, Leukemia and Lymphoma Society, White Plains, NY |
The proposed symposium is an educational course, bringing together international professionals and patient advocacy groups to discuss bone marrow failure syndromes. International perspectives on the epidemiology, pathobiology, and treatment approaches to bone marrow failure syndromes will be explored. This approach will empower the participant to develop treatment strategies that target epigenetic and other basic mechanisms for bone marrow failure disorders and correlate response to modification of the clone. Another unique aspect of this symposium is the support and active participation of educators from the Aplastic Anemia and Myelodysplastic Syndromes International Foundation and the Leukemia and Lymphoma Society, who will present methods of making clinical trials available to patients in community settings.
For more information, contact:
Roberta Stavole, Cleveland Clinic Center for Continuing Education
Phone: 216-448-0789
Fax: 216-448-0784
Management of Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers, and Novel Treatment Strategies
This program is sponsored by the Dannemiller Memorial Educational Foundation and supported by Cephalon Oncology.
| Location: | Moscone Center West, Level 3, Room 3000/3002/3004 | |
| Speakers: | Bruce D. Cheson, MD, Georgetown University Hospital, Washington, DC
|
|
| Harry Erba, MD, PhD, University of Michigan Health System, Ann Arbor, MI
|
||
| Kanti Rai, MD, Long Island Jewish Medical Center, New Hyde Park, NY
|
||
| Bart Barlogie, MD, University of Arkansas for Medical Sciences, Little Rock, AR
|
||
| Mathias Rummel, MD, PhD, Hospital of the Justus-Liebig-University of Giessen, Giessen, Germany |
This symposium will focus on the therapeutic challenges hematologists encounter when treating older patients with hematologic malignancies. With the recent introduction of targeted monoclonal antibodies, significant progress has been made in treating younger patients with hematologic tumors. However, prognosis for the older patient remains unsatisfactory, with median survival times much shorter than in the younger population. The poor survival rates are often due to therapy-related mortality, failure of induction chemotherapy, early relapse, and comorbidities. Chemoresistance is a key characteristic of acute myeloid leukemia (AML) in older patients, and small molecules may serve as alternatives to treat patients who have relapsed or were refractory to previous therapy. Allogeneic stem cell transplantation may achieve a cure in older patients with AML/MDS, but many are not eligible. This symposium will cover therapies appropriate for integration into the care of older patients with hematologic malignancies, in particular: AML, multiple myeloma, chronic lymphoid leukemia, and non-Hodgkin lymphoma. The symposium will focus on new molecular markers and the use of cytogenetics to diagnose and stratify patients, as well as treatment strategies that relate to this particular group of patients.
For more information, contact:
Robin Simak, Hemedicus, Inc.
Phone: 201-594-0400
Fax: 201-594-0409
The Changing Face of Thrombocytopenia Management: A Focus on Improving Patient
Outcomes
This program is sponsored by The France Foundation and supported by GlaxoSmithKline.
| Location: | Hilton San Francisco – Imperial Ballroom A and B | |
| Speakers: | James Bussel, MD, Weill Cornell Medical Center, New York, NY
| |
| Douglas Cines, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
|
||
| Kenneth Bauer, MD, Harvard Medical School, Boston, MA |
This symposium will provide a comprehensive update on management strategies for thrombocytopenias of different origins, including idiopathic thrombocytopenic purpura, thrombocytopenias arising secondary to other disorders, and heparin-induced thrombocytopenia. The speakers will address similarities and differences in the etiology, diagnosis, and evaluation of patients with different forms of this disorder. Attendees will also be exposed to the latest expert thinking on the management for each form, including established treatments and recent clinical trial data on emerging therapies. The management of thrombocytopenias of all types is undergoing a critical period of change, and this symposium will equip hematologists to make the most effective use of current treatments as well as new therapies as they become available.
For more information, contact:
Jennifer Fallon, The France Foundation
Phone: 860-434-1650
Fax: 860-434-5390
Multiple Myeloma: Finding Your Way Through the Treatment Maze – Selecting the Best Treatment in the Era of Novel Agents
This program is sponsored by the Postgraduate Institute for Medicine and supported by the International Myeloma Foundation.
| Location: | Moscone Center South, Exhibit Level, Room 104 | |
| Speakers: | Brian G.M. Durie, MD, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
|
|
| Antonio Palumbo, MD, University of Turin, Turin, Italy
|
||
| S. Vincent Rajkumar, MD, Mayo Clinic College of Medicine, Rochester, MN
|
||
| Jesus San Miguel, MD, PhD, Hospital Universidad de Salamanca, Salamanca, Spain |
This program will educate clinicians on phase III clinical trial data supporting the use of novel therapeutic approaches for treating myeloma in the frontline and relapsed settings. Key areas that impact therapeutic decisions, such as transplantation status, comorbidities, sequencing of therapy, and safety considerations, will be addressed throughout the cases.
For more information, contact:
Eleanor Gallelli, Clinical Care Options
Phone: 703-674-3524
Fax: 703-391-6874
Clinical Crossroads: Factors Critical to Successful Patient Management in Lymphoproliferative Disorders
This program is sponsored by Postgraduate Institute for Medicine and supported by Millennium Pharmaceuticals, Inc., and Ortho Biotech.
| Location: | Moscone Center West, Level 2, Room 2009/2011/2022/2024 | |
| Speakers: | Andre Goy, MD, The Cancer Center at Hackensack University Medical Center, Hackensack, NJ
|
|
| Anton Hagenbeek, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands
|
||
| Robert Z. Orlowski, MD, PhD, The University of Texas M. D. Anderson Cancer Center Houston, TX
|
||
| Steven P. Treon, MD, PhD, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
|
||
| Amitabha Mazumder, MD, St. Vincent’s Comprehensive Cancer Center, New York, NY |
This program seeks to provide the highest educational value to hematologists by directly asking the hematologist/oncologist members of Clinical Care Options (CCO) to define and rank the most challenging issues they face in the treatment of lymphoproliferative disorders, focusing on multiple myeloma, non-Hodgkin lymphoma, and Waldenström Macroglobulinemia. Tapping into its extensive U.S. and non-U.S. membership, CCO will conduct this needs assessment survey to identify key areas of educational priority regarding optimal patient management for lymphoproliferative disorders in advance of satellite content development. The list of issues to be explored in the survey will be created in collaboration with the faculty and CCO editorial staff. Once the results are compiled from the survey responses, the faculty and CCO editors will use those results to design the most effective cases to illustrate the key clinical considerations and evidence illuminated as challenges in the survey.
For more information, contact:
Eleanor Gallelli, Clinical Care Options
Phone: 703-674-3524
Fax: 703-391-6874
Debating the Key Clinical Questions for the Management of Patients With Multiple Myeloma
This program is sponsored by the Curatio CME Institute and supported by the Multiple Myeloma Research Foundation.
| Location: | Moscone Center West, Level 3, Room 3009/3011/3022/3024 | |
| Speakers: | Kenneth Anderson, MD, Harvard Medical School, LeBow Institute for Myeloma Therapeutics, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute, Boston, MA
|
|
| William Bensinger, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
|
||
| Sundar Jagannath, MD, St. Vincent’s Comprehensive Cancer Center, New York, NY
|
||
| Sagar Lonial, MD, Emory University School of Medicine, Atlanta, GA
|
||
| Paul Richardson, MD, Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute, Boston, MA |
The interactive format of this CME symposium is structured as a self-debate with each speaker presenting the pros and cons of a key clinical question. These questions represent those faced by physicians in their daily practice. The objective of each talk is to begin with five to 10 minutes of didactic discussion and then present the key question followed by a review of the data discussing both the pros and cons of the debate.
For more information, contact:
Kristen Petro, Curatio CME Institute
Phone: 610-363-1619, ext. 115
Fax: 610-363-7410
Integrating New Developments in MDS Into Clinical Practice
This program is sponsored by Educational Review Systems and supported by the Myelodysplastic Syndromes Foundation, Inc.
| Location: | Moscone Center South, Esplanade Level, Room 307/309 | |
| Speakers: | Alan F. List, MD, H. Lee Moffitt Cancer Center, Tampa, FL
|
|
| John M. Bennett, MD, University of Rochester, James P. Wilmot Cancer Center, Rochester, NY
|
||
| P.K. Epling-Burnett, MD, H. Lee Moffitt Cancer Center, Tampa, FL
|
||
| Guillermo Garcia-Manero, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
|
||
| Marilyn Slovak, MD, City of Hope National Medical Center, Duarte, CA
|
||
| Detlef Haase, MD, Georg-August-Universität Göttingen, Göttingen, Germany |
There has been an upsurge in new information in myelodysplastic syndrome (MDS) research, diagnosis, and treatment during the past year that continues to mold our understanding of the disease and its treatment in 2008 and beyond. This symposium has been designed to comprehensively integrate and evaluate this information that will impact diagnosis, stratification, biology, treatment, and “tracking” of MDS patients. A thorough overview of the upsurge in unique therapies under investigation will be presented; cutting-edge information on the role of immunopathology in MDS will be explored; improvements in the morphologic classification and diagnosis of MDS will be explained (International Working Group on MDS Morphology); innovative new research designed to broaden knowledge and improve techniques in testing for and analysis of MDS cytogenetics will be presented by the International Working Group on MDS Cytogentics; the evolution of the prognostic scoring systems for MDS (IPSS and WPSS) aimed at improving patient stratification will be presented; a new state-of-the-art methodology to “track” MDS patients that is designed to provide real-time alerts to the clinician regarding disease progression and/or response to MDS therapy will be discussed; and, finally, the path(s) that will make combination therapy a reality for MDS patients will be explored.
For more information, contact:
Nancy Mrzljak, MDS Foundation
Phone: 800-637-0839
Fax: 609-298-0590
New Perspectives, New Strategies in Venous Thromboembolic Disease
This program is sponsored by The University of Cincinnati and supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
| Location: | San Francisco Marriott – Yerba Buena Ballroom, Salon 9 | |
| Speakers: | Jeffrey Weitz, MD, Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
|
|
| Charles T. Esmon, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
|
||
| Alexander G.G. Turpie, MD, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
|
||
| Richard Joel Friedman, MD, Charleston Orthopaedic Associates, Charleston, SC |
This CME-accredited symposium will consider guidelines-based pharmacologic strategies for primary and secondary thromboprophylaxis in patients at risk of venous thromboembolic (VTE) disease, deep-vein thrombosis, and pulmonary embolism, and for treatment of VTE. Disjunctions between guideline recommendations and actual clinical practice (and the reasons potentially underlying them) will be explored. Data concerning pharmacologic agents that are under development and may impact prophylaxis and treatment of VTE will be presented. Formal presentations will be followed by interactive case studies.
For more information, contact:
Carol Ann Goode, The Exeter Group
Phone: 212-644-1017
Fax: 212-644-6762